Inhibition of RKIP aggravates thioacetamide-induced acute liver failure in mice

Area of Science:

• Biochemistry
• Molecular Biology
• Hepatology

Background:

• Raf kinase inhibitor protein (RKIP) is implicated in various intracellular signaling pathways.
• Abnormal RKIP expression is linked to tumor progression and metastasis.
• The specific role of RKIP in acute liver injury remains largely unknown.

Purpose of the Study:

• To investigate the role of RKIP in thioacetamide-induced acute liver injury in mice.
• To determine the effect of RKIP down-regulation on hepatic damage and related molecular pathways.

Main Methods:

• Acute liver failure was induced using thioacetamide in a mouse model.
• Locostatin was administered to inhibit RKIP expression.
• Liver injury markers (ALT, AST), oxidative stress (ROS), inflammatory factors (TNF-α, IL-6, IL-1β), and key signaling pathways (NF-κB, ERK, Nrf2/HO-1) were assessed.

Main Results:

• Locostatin significantly inhibited RKIP expression, leading to severe liver injury and elevated ALT/AST levels.
• Reduced RKIP expression increased reactive oxygen species and pro-inflammatory cytokines (TNF-α, IL-6, IL-1β).
• Down-regulation of RKIP decreased Nrf2/HO-1 levels and promoted NF-κB and ERK pathway activation.

Conclusions:

• RKIP exhibits a protective effect against acute liver injury.
• A decrease in RKIP expression exacerbates hepatic injury by promoting oxidative stress, inflammation, and activating detrimental signaling pathways.
• RKIP represents a potential therapeutic target for acute liver failure.